# Burden of Herpes Zoster in selected immunocompromised populations in the German Pharmacoepidemiological Research Database (GePaRD)

**First published: 25/01/2017** 

Last updated: 29/03/2024





# Administrative details

#### **PURI**

https://redirect.ema.europa.eu/resource/17403

#### **EU PAS number**

**EUPAS17402** 

#### Study ID

17403

#### **DARWIN EU® study**

No

# Study countries Germany

#### **Study description**

Based on data from statutory health insurance providers, the study investigates the incidence of herpes zoster in patients with different severities of immunosuppression. Besides, frequencies of complications and different aspects of healthcare resource utilisation are examined for herpes zoster patients stratified by severity of immunosuppression.

#### **Study status**

**Finalised** 

## Research institutions and networks

## **Institutions**

Leibniz Institute for Prevention Research and
Epidemiology - BIPS
Germany
First published: 29/03/2010
Last updated: 26/02/2024
Institution Not-for-profit ENCePP partner

## Contact details

## Study institution contact

#### Oliver Riedel

Study contact

riedel@leibniz-bips.de

## **Primary lead investigator**

Oliver Riedel

**Primary lead investigator** 

# Study timelines

## Date when funding contract was signed

Planned: 03/04/2015

Actual: 01/06/2015

#### Study start date

Planned: 20/07/2015

Actual: 01/12/2015

## Data analysis start date

Planned: 10/08/2015

Actual: 04/01/2016

## Date of final study report

Planned: 10/06/2016

Actual: 30/11/2016

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

GlaxoSmithKline Biologicals S.A.

## Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

# Study type

# Study type list

## **Study topic:**

Disease /health condition

### **Study type:**

Non-interventional study

#### Scope of the study:

Disease epidemiology

#### **Data collection methods:**

Secondary use of data

#### Main study objective:

To estimate the incidence of herpes zoster and its complications in immunocompromised subjects, aged 18 years and above, overall and stratified by sex, age group, and type of immunocompromising disease or therapy.

# Study Design

#### Non-interventional study design

Cohort

Cross-sectional

# Study drug and medical condition

#### Medical condition to be studied

Herpes zoster

# Population studied

## Short description of the study population

Patients aged 18 years and above with different severities of immunosuppression.

#### Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

#### **Special population of interest**

**Immunocompromised** 

#### **Estimated number of subjects**

1260000

# Study design details

#### **Outcomes**

Incidence of herpes zoster. Prevalence of herpes zoster complications and frequencies of hospitalisations, physician visits, and treatments with antivirals and analgesics.

#### **Data analysis plan**

A cross-sectional design will be used to identify patients with different severities of immunosuppression for the years 2006-2012 based on immunocompromising diseases and drug treatments. A cohort design will be used to calculate annual incidence rates of herpes zoster for the years 2006-2012, stratified by age, sex, and severity of immunosuppression and to analyse the prevalence of herpes zoster complications, physician visits, hospitalisations, and antiviral and analgesic treatments.

## Data management

## Data sources

#### Data source(s)

German Pharmacoepidemiological Research Database

#### **Data sources (types)**

Administrative healthcare records (e.g., claims)

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

## **Check logical consistency**

Unknown

## Data characterisation

#### **Data characterisation conducted**

Unknown